“A phenomenal teacher, surgeon and clinician. It was a privilege to learn from Jorge during my two years at Charles Retina. I would trust Jorge with my closest friend and/or family. The best hands I've seen in my career- Brilliant surgeon. ”
About
-Instagram: jordical_retina
-Twitter:…
Activity
-
Ramanath Bhandari, MD, FASRS, of RevOpsis Therapeutics discusses the development of RO-104 for the treatment of retinal disease. 🔗…
Ramanath Bhandari, MD, FASRS, of RevOpsis Therapeutics discusses the development of RO-104 for the treatment of retinal disease. 🔗…
Liked by Jorge Calzada
-
Join us at Octane OC Opthalmology Tech Forum 2024 on June 20-21 in Newport Beach! John Pollack, MD will be participating on the panel "Innovations…
Join us at Octane OC Opthalmology Tech Forum 2024 on June 20-21 in Newport Beach! John Pollack, MD will be participating on the panel "Innovations…
Liked by Jorge Calzada
-
Thank you to Arshad M. Khanani, Jeff Heier, and Peter Kaiser for the opportunity to present the safety of Avacincaptad Pegol in the GATHER clinical…
Thank you to Arshad M. Khanani, Jeff Heier, and Peter Kaiser for the opportunity to present the safety of Avacincaptad Pegol in the GATHER clinical…
Liked by Jorge Calzada
Experience & Education
Publications
-
Ocular histoplasmosis syndrome.
Survey of ophthalmology
Ocular histoplasmosis syndrome (OHS) is a chorioretinal disorder with a distinct fundus appearance that is commonly found in regions endemic for Histoplasma capsulatum. Choroidal neovascularization (CNV) secondary to OHS is considered one of the principal causes of central vision loss among young adults in endemic areas. Although there is no consensus regarding its pathogenesis, evidence points to Histoplasma capsulatum as the most probable etiology. Once considered an intractable hemorrhagic…
Ocular histoplasmosis syndrome (OHS) is a chorioretinal disorder with a distinct fundus appearance that is commonly found in regions endemic for Histoplasma capsulatum. Choroidal neovascularization (CNV) secondary to OHS is considered one of the principal causes of central vision loss among young adults in endemic areas. Although there is no consensus regarding its pathogenesis, evidence points to Histoplasma capsulatum as the most probable etiology. Once considered an intractable hemorrhagic maculopathy, CNVs are now treatable. Extrafoveal CNVs are successfully treated with laser photocoagulation. Subfoveal and juxtafoveal CNVs are managed with anti-vascular endothelial growth factor therapy, photodynamic therapy, or a combination of both. Modern imaging technologies such as spectral-domain optical coherence tomography have improved our diagnostic abilities, making it easier to monitor disease activity and CNV regression. We review the epidemiology, pathogenesis, clinical manifestations, differential diagnosis, and current treatment of this disease.
Other authorsSee publication -
comparison of morphologic features of macular proliferative vitreoretinopathy and idiopathic epimacular membrane.
retina (philadelphia, pa.)
to compare the spectral-domain optical coherence tomography morphologic features and visual characteristics of a series of patients with epimacular membrane with and without a history of retinal breaks.
-
Spectral domain optical coherence tomography characteristics of retained subretinal perfluoro-n-octane.
Retinal cases & brief reports
To describe the spectral domain optical coherence tomography characteristics of retained subretinal perfluoro-n-octane (SR-PFO) after vitreoretinal surgery.
Other authorsSee publication -
Vitreous Microsurgery
Lippincott Williams & Wilkins
-
Please find updated scientific publication list on https://www.researchgate.net
-
Projects
-
Baptist Women's and Children's Hospital Pediatric Ophthalmology Center
Center for comprehensive diagnosis and management of pediatric ophthalmic diseases. Children with retinal disorders can have evaluations under anesthesia with diagnostic imaging and vitrectomy surgery as needed.
-
Deep Blue Retina
-
Creation of a new vitreoretinal clinic in the Memphis Metro region.
-
CRI: Clinic and Office Building
-
Languages
-
English
Native or bilingual proficiency
-
Spanish
Native or bilingual proficiency
Recommendations received
2 people have recommended Jorge
Join now to viewMore activity by Jorge
-
CNV type 2 , beauty of neovascular network with Dream OCT ,Intalight . No compromise between peripheral analysis and macular analysis in OCTA…
CNV type 2 , beauty of neovascular network with Dream OCT ,Intalight . No compromise between peripheral analysis and macular analysis in OCTA…
Liked by Jorge Calzada
-
Take a look at our new Life Science Center in Memphis! This facility and the team there play an important role in ensuring critical healthcare…
Take a look at our new Life Science Center in Memphis! This facility and the team there play an important role in ensuring critical healthcare…
Liked by Jorge Calzada
-
Erin Henry, VP of Product Strategy and Innovation at Iveric Bio, An Astellas Company, discusses IZERVAY (avacincaptad pegol intravitreal solution)…
Erin Henry, VP of Product Strategy and Innovation at Iveric Bio, An Astellas Company, discusses IZERVAY (avacincaptad pegol intravitreal solution)…
Liked by Jorge Calzada
-
I implanted my first Johnson & Johnson Vision Tecnis Odyssey multifocal lens today. Thanks to Briana Cupello (in red) for walking me through it. I’m…
I implanted my first Johnson & Johnson Vision Tecnis Odyssey multifocal lens today. Thanks to Briana Cupello (in red) for walking me through it. I’m…
Liked by Jorge Calzada
-
Thanks to all for making 2024 ARVO Annual Meeting so fantastic!
Thanks to all for making 2024 ARVO Annual Meeting so fantastic!
Liked by Jorge Calzada
-
On May 8, we are opening our new West Coast Innovation Center in South San Francisco, uniting our leading #CellAndGene therapy capabilities under one…
On May 8, we are opening our new West Coast Innovation Center in South San Francisco, uniting our leading #CellAndGene therapy capabilities under one…
Liked by Jorge Calzada
-
The 2024 ARVO meeting is in the books! Had the amazing opportunity to represent Astellas Pharma help showcase our pipeline, refine our knowledge with…
The 2024 ARVO meeting is in the books! Had the amazing opportunity to represent Astellas Pharma help showcase our pipeline, refine our knowledge with…
Liked by Jorge Calzada
-
Enormously proud of the interim data from the RGX-381 ocular #CLN2 first-in-human #genetherapy trial, presented by Rob Henderson today at #ARVO2024.…
Enormously proud of the interim data from the RGX-381 ocular #CLN2 first-in-human #genetherapy trial, presented by Rob Henderson today at #ARVO2024.…
Liked by Jorge Calzada
-
jCyte, Inc. is excited to be at the Foundation Fighting Blindness Retinal Cell and Gene Therapy Innovation Summit in Seattle. John Pollack, MD will…
jCyte, Inc. is excited to be at the Foundation Fighting Blindness Retinal Cell and Gene Therapy Innovation Summit in Seattle. John Pollack, MD will…
Liked by Jorge Calzada
-
Many thanks to The Ophthalmologist for including me again in their Power List. It is a real priveledge to join my friends, and the colleagues I…
Many thanks to The Ophthalmologist for including me again in their Power List. It is a real priveledge to join my friends, and the colleagues I…
Liked by Jorge Calzada
-
Thank you, Dr. Vitaly Man, for highlighting and capturing the essence of BEYEONICS™ One system and its significant impact on ophthalmic…
Thank you, Dr. Vitaly Man, for highlighting and capturing the essence of BEYEONICS™ One system and its significant impact on ophthalmic…
Liked by Jorge Calzada
-
Prof. Paulo Eduardo Stanga of The Retina Clinic London, discusses the importance of collaboration between #optometrists and #ophthalmologists. 🔗…
Prof. Paulo Eduardo Stanga of The Retina Clinic London, discusses the importance of collaboration between #optometrists and #ophthalmologists. 🔗…
Liked by Jorge Calzada
-
I had an exceptional time at the NIH BRIDGE2AI All Hands and Open House Conference in Rockville, MD from April 17-19, 2024! Engaging discussions…
I had an exceptional time at the NIH BRIDGE2AI All Hands and Open House Conference in Rockville, MD from April 17-19, 2024! Engaging discussions…
Liked by Jorge Calzada
Other similar profiles
-
Brendan Girschek MD FRCSC FACS
Vitreoretinal Surgeon - Barnet Dulaney Perkins Eye Center, Flagstaff AZ
Connect -
David RP Almeida MD MBA PhD
Innovative Retina Surgeon Director of Clinical Research @ Erie Retina Research President & CEO Case X Global
Connect -
Robert Masson MD, FACS FAANS
CEO and Founder, eXeX™ | Neurosurgeon | Explorer | Digital Twin for Surgery
Connect -
Bradley Barnett
Connect -
John A. Cunningham
Connect -
Jason Brenner
Cornea, Cataract and Refractive Surgeon
Connect -
SAMIR MELKI
Founder and Medical Director at Boston Vision
Connect -
Mahi Muqit
Connect -
Cheryl Lockhart, DNP, CCNS, CEN, CHSE
Retired AF Sr Officer passionately changing military medical readiness through Virtual Reality.
Connect -
Omar Shakir
Pioneering Office-Based Retina Surgery, Cataract/Retina/Refractive surgeon, Entrepreneur, Innovator, Educator, Speaker
Connect
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Jorge Calzada in United States
-
Jorge Calzada
-
Jorge Calzada
-
Jorge Calzada
Mighty1 Logistics
-
Jorge Calzada
Field Foreman | Christian Brothers Mechanical Services | Hvac
16 others named Jorge Calzada in United States are on LinkedIn
See others named Jorge Calzada